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CCDC6 is rearranged in approximately 20% of papillary thyroid carcinomas and some lung cancers
participating in the formation of PTC1/ret proto-oncogene oncogene. CCDC6 is involved in the cellu-
lar response to DNA damage and is stabilized by ATM-mediated phosphorylation at Thr434. How-
ever, the E3 ligase that targets CCDC6 for destruction is unknown. Here, we show that FBXW7
interacts with and targets CCDC6 for ubiquitin-mediated proteasomal degradation. Moreover,
FBXW7-mediated CCDC6 degradation is impaired in response to DNA damage. Mechanistically,
phosphorylation of CCDC6 at Thr434 by ATM during DNA damage response prevents FBXW6-CCDC6
interaction and FBXW7-mediated CCDC6 degradation. Our results suggest that the involvement of
FBXW7 in targeting CCDC6 for destruction will be useful for the establishment of new therapeutic
approaches for cancer treatment.
Structured summary of protein interactions:
FBXW7 physically interacts with CCDC6 by anti bait coimmunoprecipitation (View Interaction: 1, 2)
FBXW7 physically interacts with CCDC6 and CUL1 by anti tag coimmunoprecipitation (View Interaction:
1, 2)
FBXW7 physically interacts with CCDC6 by anti tag coimmunoprecipitation (View Interaction: 1, 2, 3, 4, 5)
CCDC6 physically interacts with SKP1 and CUL1 by anti bait coimmunoprecipitation (View interaction)
FBXO6 physically interacts with CUL1 by anti tag coimmunoprecipitation (View interaction)
FBXW2 physically interacts with CUL1 by anti tag coimmunoprecipitation (View interaction)
FBXO4 physically interacts with CUL1 by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction deed, CCDC6 was found to be phosphorylated at Thr434 byCCDC6 (coiled–coil domain containing 6, also known as PTC1,
Protein H4 or D10S170) encodes for a ubiquitously expressed
and highly preserved protein, that is frequently rearranged in hu-
man malignances [1–3]. It was initially isolated and characterized
because of its participation in PTC1/ret proto-oncogene (RET) onco-
gene, which is present in approximately 20% of papillary thyroid
carcinoma (PTC) cases [4,5]. Other rearrangements involving
CCDC6 have also been identiﬁed, including H4/PDGFRb, the fusion
gene product of the translocationt (5;10)(q33;q22), occurring in
sporadic cases of atypical chronic myeloid leukemia [6]. Recently,
PTC1/RET has also been found in lung cancer [7].
CCDC6 was reported to be involved in DNA repair [8]. CCDC6
is heavily phosphorylated at multiple sites identiﬁed by MS
from multiple groups [9–15], indicating the post-translational
modiﬁcations of CCDC6 should play roles in its regulation. In-chemical Societies. Published by E
. JunGang).ATM in cells treated with etoposide or ionizing radiation (IR)
[16]. Phosphorylated CCDC6 has a longer half-life and more
resistant to ubiquitin- mediated proteasomal degradation.
Expression of CCDC6 with threonine 434 mutated in Alanine
protected cells from genotoxic stress-induced apoptosis [16].
However, the E3 ligase that responsible for the destruction of
CCDC6 is still unknown.
FBXW7 (F-box and WD repeat domain-containing 7, also
known as hCDC4) is the substrate recognition component of an
evolutionarily conserved SCF (complex of SKP1, CUL1, and F-box
protein)-type ubiquitin ligase complexes [17]. SCF-FBXW7 acts
as a tumor suppressor in several tissues and targets multiple tran-
scriptional activators and protooncogenes for ubiquitin-mediated
degradation [18], including cyclin E [19], c-Myc [20], Notch [21],
c-Jun [22], mammalian target of rapamycin [23], and MCL1
[24,25]. Mutations in the FBXW7 gene are found in ovarian [26],
breast [27], endometrial [28], lymphoma [29] and colorectal
cancers [30]. SCF-FBXW7 binds and regulates the abundance of
proteins in a phosphorylation-dependent manner and the knownlsevier B.V. All rights reserved.
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degrons (CPD) sequence (T/S)PXX(S/T/E) in which the T/S residue
can be phosphorylated by the kinase GSK3b [19,31–33]. FBXW7
comprises eight WD40 repeats which encode propellor blade
structures that bind the CPD of its targets through arginine resi-
dues at the propellor tips [34].
Here, we show that FBXW7 interacts with and targets CCDC6
for ubiquitin-mediated proteasomal degradation in lung cancer
cells. We also provide evidences that FBXW7-mediated CCDC6
degradation is impaired during DNA damage response. Moreover,
phosphorylation of CCDC6 by the ATM kinase during DNA damage
response prevents FBXW7-CCDC6 interaction and FBXW7-
mediated CCDC6 degradation. These ﬁndings help us understand
the post-translational regulatory mechanism of CCDC6 in DNA
damage response.
2. Materials and methods
2.1. Cell culture and drugs
293T and A549 cells were cultured in Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen) supplemented with 10% fetal calf
serum (Gibco BRL, Gaithersburg, MD) in a 5% CO2/95% air at
37 C. B-lymphocyte cell lines GM02184 (wild type, ATM+/+)
and GM01526 (ATM/) were purchased from Coriell Cell Repos-
itories and cultured in RPMI medium 1640 supplemented with
10% fetal calf serum. DMSO and drugs in this work were pur-
chased from sigma.
2.2. Antibodies
Antibodies were obtained from the following sources: anti-
CCDC6 (Santa Cruz Biotech, Santa Cruz, CA), anti-CUL1(Santa Cruz
Biotech, Santa Cruz, CA), anti-SKP1(Santa Cruz Biotech, Santa Cruz,
CA), anti-HA (Santa Cruz Biotech, Santa Cruz, CA), anti-Actin (Cell
Signaling, Beverly, MA), anti-FBXW7 (Sigma, USA) and anti-Flag
M2 (Sigma, USA).
2.3. Plasmids and transfection
CCDC6, FBXW1, FBXW2, FBXW7, FBXO4 and FBXO6 were ampli-
ﬁed from HeLa cells by PCR and cloned into the pBabe retroviral
vector. All DN-Cullins were ampliﬁed from a 293T cDNA library
and cloned into pcDNA.3.1 vector. CCDC6 mutant plasmids were
generated using QuickChange Site-Directed Mutagenesis Kit (Strat-
agene). All cDNAs were completely sequenced. All the transient
transfections were conducted using Lipofectamine 2000 (Invitro-
gen) according to the manufacturer’s instructions.
2.4. RNA isolation and Real-time PCR analysis
Total RNA was isolated from tissues or cells using TRIzol (Invit-
rogen) according to the manufacturer’s instructions. In order to
quantify the transcripts of the interest genes, Real-time PCR was
performed using a SYBR Green Premix Ex Taq (Takara, Japan) on
LightCycler 480 (Roche, Switzerland). The primers used were avail-
able upon request.
2.5. RNA interference
To generate retroviral vectors expressing short hairpin RNAs di-
rected against human FBXW7, the following oligos were annealed
and ligated into the BamHI and EcoRI sites of RNAi-Ready pSIRENp-
uro retroviral vector (Clontech): FBXW7-shRNA-1, GAAUGGA
ACUCAAAGACAA; FBXW7-shRNA-2 GGGACAUACAGGUGGAG UA.2.6. Western blotting
Cells were harvested and lysed with ice-cold lysis buffer
(62.5 mM Tris–HCl, pH 6.8, 100 mM DTT, 2% w/v SDS, 10% glyc-
erol). After centrifugation at 20,000g for 10 min at 4 C, proteins
in the supernatants were quantiﬁed and separated by 10% or 12%
SDS–PAGE, either stained by Coomassie Brilliant Blue or trans-
ferred to NC membrane (Amersham Bioscience, Buckinghamshire,
UK). After blocking with 5% non-fat milk in PBS, membranes were
immunoblotted with antibodies as indicated, followed by HRP-
linked secondary antibodies (Cell Signaling). The signals were de-
tected by SuperSignal West Pico Chemiluminescent Substrate kit
(Pierce, Rockford, IL) according to manufacturer’s instructions.
2.7. Immunoprecipitation
Cells were lysed in 4 ml of lysis buffer (50 mM Tris–HCl pH 7.5,
250 mM NaCl, 0.5% Non-idet P40, Roche complete EDTA-free pro-
tease inhibitor cocktail) for 20 min with gentle rocking at 4 C. Ly-
sates were cleared using centrifugation (13,000 rpm, 10 min), the
supernatant was subjected to immunoprecipitation (IP) with
20 ll of anti-HA afﬁnity resin (Sigma) overnight at 4 C with gentle
inversion. Resin containing immune complexes was washed with
1 ml ice cold lysis buffer 4 times followed by three 1 ml Tris Buf-
fered Saline (TBS) washes. Precipitates were denatured in gel load-
ing buffer at 95 C for 5 min.
2.8. Cycloheximide inhibition test
Cells were treated with 20 lg/ml cycloheximide (CHX, Sigma–
Aldrich) for the indicated time points with or without MG132.
The expression of CCDC6 protein was measured by Western blots
with actin as loading control.
2.9. Statistical analysis
The values were expressed as mean ± S.D. The paired t test was
used for statistical analysis between two groups. Signiﬁcant level
was set at P < 0.05.
3. Results
3.1. Cullin1-based ubiquitin E3 ligase is required for the degradation of
CCDC6
To test whether CCDC6 is degradated in lung cancer cells, we
treated A549 and HeLa cells with proteasome inhibitors MG132
or PS341. In agreement with the previous report [16], both protea-
some inhibitors signiﬁcantly increased the expression of CCDC6,
indicating CCDC6 is a short-lived protein and a substrate of ubiqui-
tin–proteasome system (Figs. 1A and B). However, we did not ob-
serve a signiﬁcant phosphorylation doublet in both cell lines [35],
that may duo to different anti-CCDC6 antibody. Because the Cullin-
based ubiquitin E3 ligases are involved in the degradation of many
key proteins during DNA damage response and because CCDC6 is
involved in DNA damage response [16], we tested whether a
Cullin-based ubiquitin E3 ligase is required for the degradation of
CCDC6. Four dominant negative (DN) Cullin members, including
DN-Cullin1, DN-Cullin2, DN-Cullin3 and DN-Cullin4A, were ex-
pressed into A549 cells for 36 h. As shown in Fig. 1C, among those
DN-Cullin members, only DN-Cullin1 could signiﬁcantly prevent
the degradation of CCDC6, indicating CCDC6 maybe a substrate
of a SCF E3 ligase. To further prove this possibility, we then tested
whether CCDC6 interacts with the components of SCF complex.
Endogenous CCDC6 was immunoprecipitated by CCDC6 antibody
Fig. 1. Cullin1-based ubiquitin E3 ligase is required for the degradation of CCDC6. (A) A549 cells were treated with proteasome inhibitors 20 lM MG132 or 1 lM PS341 for
8 h, cell lysates were subjected to immunoblot analysis (IB) with indicated antibodies. (B) HeLa cells were treated with proteasome inhibitors 20 lM MG132 or 1 lM PS341
for 8 h, cell lysates were subjected to immunoblot analysis (IB) with indicated antibodies. (C) Dominant (DN) Cullins plasmids were transfected into A549 cells for 36 h, cell
lysates were subjected to IB with indicated antibodies. (D) Lysates of A549 cells were subjected to immunoprecipitation (IP) with antibodies to CCDC6 or with control mouse
immunoglobulin G (IgG) followed by immunoblot (IB) with indicated antibodies.
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precipitated CCDC6 complex (Fig. 1D). These results suggest that
CCDC6 associates with the SCF E3 ligase complex in vivo.
3.2. FBXW7 interacts with CCDC6
Because SCF E3 ligases usually recognize the phosphor-degron
of their substrates [17], we therefore checked the protein se-
quences of CCDC6. We noticed that there are three potential CPD
sequences in CCDC6, which is also present in the FBXW7 substrates
cyclin E and c-Myc (Fig. 2A). We thus tested whether FBXW7 inter-
acts with CCDC6. We expressed the HA-tagged F-box proteins
FBXW2, FBXW7, FBXO4, and FBXO6 together with FLAG-tagged
CCDC6 in 293T cells. Cell lysates were subjected to immunoprecip-
itation with antibodies to HA, and the resulting precipitates were
subjected to immunoblot analysis with antibodies to FLAG or
CUL1. FLAG-CCDC6 was co-precipitated by HA antibody in the
presence of HA-FBXW7, whereas HA-tagged FBXW2, FBXO4, and
FBXO6 were not able to co-precipitate FLAG-CCDC6 (Fig. 2B). These
results suggested that FBXW7 interacts with CCDC6 and might tar-
get it for ubiquitylation.
To determine whether FBXW7 interacts with endogenous
CCDC6, 293T cell lysates were subjected to immunoprecipitation
with antibodies to CCDC6 or with control mouse immunoglobulin
G (IgG). FBXW7 was co-precipitated by CCDC6 antibody but not by
the control IgG antibody (Fig. 2C), indicating that endogenous
CCDC6 associates with FBXW7.
To determine whether phosphorylation of S359, S413 and T427
of CCDC6 is required for the binding of FBXW7, we performed
in vivo analysis of the interaction between FBXW7 and CCDC6 mu-
tants (S359A, S413A, T427A and S359A/S413A/T427A) in which
either or all predicted phosphorylation sites were replaced by ala-
nine. In transfected 293T cells, wild-type CCDC6 interacted with
FBXW7, whereas the S359A/S413A/T427A mutant did not
(Fig. 2D), suggesting that phosphorylation of CCDC6 on S359,
S413 and T427 is required for interaction with FBXW7.
3.3. FBXW7 regulates the stability of CCDC6
These results prompted us to test whether FBXW7 is involved in
regulating the stabilityofCCDC6protein. To this end,293Tcellsweretransfected with CCDC6 and either FBXW1 or FBXW7. Whereas the
expression of FBXW1 had no observable effect on CCDC6 stability,
the expression of FBXW7 resulted in a decrease in the half-life of
CCDC6 (Fig. 3A), which was efﬁciently counteracted by the addition
of MG132 (Figs. 3B, C). However, force-expressed FBXW7 did not
cause the decrease of CCDC6 S359A/S413A/T427A mutant
(Fig. 3D), suggesting FBXW7 regulates the destruction of CCDC6 in
a phosphorylation dependentmanner.We also used two small hair-
pin RNA (shRNA) constructs to reduce the expression of FBXW7 in
A549 cells. Although both constructs targeted FBXW7, construct 1
was a litter more efﬁcient in silencing FBXW7 expression (Fig. 3E).
Accordingly, both constructs induced an increase in the half-life of
CCDC6, but construct 1 produced a more robust effect (Fig. 3F).
3.4. FBXW7-mediated CCDC6 degradation is impaired in response to
DNA damage
Given the fact that CCDC6 is stabilized by DNA damage, the ef-
fect of FBXW7 on CCDC6 stability during DNA damage response
was analyzed. In agreement with the previous report [16], CCDC6
was up-regulated in A549 cells treated with various DNA damage
reagents, including VP1 and Doxorubincin (Dox) (Fig. 4A). How-
ever, the mRNA level of CCDC6 was unchanged (Fig. 4B). Because
CCDC6 was targeted for destruction by FBXW7, we hypothesize
this process could be hampered during DNA damage response. To
test this possibility, we performed immunoprecipitation experi-
ments in A549 cells co-expressed FBXW7 and CCDC6 with or with-
out DNA damage regent VP16. Remarkably, the interaction
between the two proteins was decreased after treatment with
VP16 (Fig. 4C). However the interaction between FBXW7 and
CUL1 was not affected (Fig. 4C). Moreover, unlike CCDC6WT,
S359A/S413A/T427A mutant protein did not further increase in re-
sponse to VP16 (Fig. 4D). These data suggested that FBXW7-CCDC6
interaction was reduced and FBXW7-mediated CCDC6 degradation
was impaired in lung cancer cells during DNA damage response.
3.5. Phosphorylation of CCDC6 at Thr434 by ATM during DNA damage
response prevents FBXW7-mediated CCDC6 degradation
Because ATM-mediated phosphorylation of CCDC6 at T434 is a
stabilization signal for CCDC6 during DNA damage response [16],
Fig. 2. FBXW7 interacts with CCDC6. (A) The Cdc4 phospho-degron (CPD) sequences of human c-Myc, cyclin E and CCDC6. (B) 293T cells were transfected with vectors for
FLAG-CCDC6 and either HA-FBXW2, HA-FBXW7, HA-FBXO4, or HA-FBXO6, as indicated, and were then incubated with MG132 for 6 h. Cell lysates were subjected to IP with
antibodies to HA, and the resulting precipitates were subjected to IB with indicated antibodies. (C) Lysates of 293T cells were subjected to immunoprecipitation (IP) with
antibodies to CCDC6 or with control mouse immunoglobulin G (IgG) followed by immunoblot (IB) with indicated antibodies. (D) 293T cells transfected with indicated
plasmids for 36 h, Cell lysates were subjected to IP with antibodies to HA, and the resulting precipitates as well as cell lysates (5% as input) were subjected to IB with indicated
antibodies.
Fig. 3. FBXW7 regulates the stability of CCDC6. (A) 293T cells were transfected with CCDC6 and either HA-FBXW1 or HA-FBXW7 for 36 h, cell lysates were subjected to IB
with indicated antibodies. (B) 293T cells were transfected with HA-FBXW7 for 36 h and then cells were treated with or with 20 lMMG132 for additional 8 h, cell lysates were
subjected to IB with indicated antibodies. (C) 293T cells were transfected with CCDC6 alone or in combination with HA-FBXW7 in the presence or absence of 20 lg/ml CHX for
the indicated times (with or without MG132). The quantiﬁcation of CCDC6 half-life was determined. (D) 293T cells were transfected with Flag-CCDC6 S359A/S413A/T427A
mutant and HA-FBXW7 for 36 h, cell lysates were subjected to IB with indicated antibodies. (E) A549 cells transfected with non-speciﬁc or FBXW7 shRNAs were subjected to
Western blot with indicated antibodies. (F) A549 cells were transfected with non-speciﬁc or FBXW7 shRNAs in the presence or absence of 20 lg/ml CHX for the indicated
times. The quantiﬁcation of CCDC6 half-life was determined.
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Fig. 4. FBXW7-mediated CCDC6 degradation is impaired in response to DNA damage. (A) A549 cells were treated with various DNA damage reagents, including VP16, and
Doxorubincin (Dox) for 24 h, cell lysates were subjected to IB with indicated antibodies. (B) The mRNA of CCDC6 from A549 cells treated with various DNA damage reagents
were analyzed by Real-time PCR. There is no signiﬁcant statistic difference in CCDC6 mRNA between DMSO treatment and DNA damage reagents treatments. (C) A549 cells
co-expressed FBXW7 and CCDC6 for 24 h, and then treated with or without 20 lM DNA damage regent VP16 for additional 24 h. Cell lysates were subjected to IP with
antibodies to HA, and the resulting precipitates were subjected to IB with antibodies to the indicated antibodies. (D) A549 cells transfected with either Flag-CCDC6 WT or
Flag-CCDC6 S359A/S413A/T427A mutant for 24 h were treated with VP16 for additional 24 h, cell lysates were subjected to IB with indicated antibodies.
Fig. 5. Phosphorylation of CCDC6 at Thr434 by ATM during DNA damage response prevents FBXW7-mediated CCDC6 degradation. (A) GM00536 (ATM+/+) and GM01526
(ATM/) cells were treated with or without 20 lM VP16 for 24 h, cell lysates were subjected to IB with indicated antibodies. (B) GM00536 (ATM+/+) and GM01526 (ATM/)
cells were treated with or without 20 lM VP16 for 24 h, lysates of these cells were subjected to immunoprecipitation with FBXW7 antibody followed by IB with indicated
antibodies. (C) FLAG-tagged versions of CCDC6 and CCDC6 (T434A) mutant were co-expressed with HA-FBXW7 in 293T cells and then immunoprecipitated with antibody to
HA and followed by immunoblot (IB) with indicated antibodies. (D) A549 cells were co-expressed HA-FBXW7 and Flag-CCDC6 (T434A) mutant for 36 h, cell lysates were
subjected to IB with indicated antibodies. (E) A549 cells stably expression Flag-CCDC6 (T434A) mutant were transfected with non-speciﬁc or FBXW7 shRNAs for 36 h, cell
lysates were subjected to Western blot with indicated antibodies.
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degradation. To investigate the role of ATM in FBXW7-mediated
CCDC6 degradation, we utilized GM00536 (ATM+/+) and
GM01526 (ATM/) cells. Indeed, DNA damage-induced CCDC6
stabilization was observed in ATM+/+ but not in ATM/ cells
(Fig. 5A). Moreover, in contrast to ATM+/+ cells, DNA damage insultsdid not affect the FBXW7-CCDC6 interaction in ATM/ cells
(Fig. 5B). To further investigate the underline mechanisms, we then
check whether FBXW7 interacts with CCDC6 (T434A) mutant.
FLAG-tagged versions of CCDC6 wild-type (WT) and CCDC6
(T434A) mutant were co-expressed with HA-FBXW7 in 293T cells
and then immunoprecipitated to evaluate their interaction. As
4262 Z. JunGang et al. / FEBS Letters 586 (2012) 4257–4263depicted in Fig. 5C, only CCDC6 WT interacted with FBXW7.
Accordingly, manipulating the expression of FBXW7 in A549 cells
had no effect on the stability of CCDC6 (T434A) mutant (Figs. 5D
and E). Taken together, these results suggested that ATM prevented
FBXW7-mediated CCDC6 degradation during DNA damage re-
sponse was most likely due to decreased ability of CCDC6
(T434A) to bind to FBXW7.
4. Discussion
This is the ﬁrst study to report that CCDC6 protein degradation is
targeted by the SCF-FBXW7 E3 ligase and ATM kinase prevents this
event duringDNAdamage response.We provide several lines of evi-
dence to support that FBXW7 targets CCDC6 protein for ubiquitin-
mediated proteasomal degradation and this process was inhibited
by DNA damage response. First, CCDC6 contains three potential
CPD domains and is a substrate of SCF E3 ligase. Second, FBXW7
interacts with CCDC6 in a phosphorylation dependent manner.
Third, FBXW7 over-expression decreases CCDC6 protein level and
half-life. Forth, silencingof FBXW7 increases the endogenousCCDC6
protein level and half-life in lung cancer cells.More importantly, the
phosphorylation of CCDC6 at T434 by ATM prevents FBXW7 to bind
to and target CCDC6 for ubiquitination and degradation.
The FBXW7 gene is found within 4q32, a chromosomal region
that is mutated in approximately 30% of all human cancers [36,37].
Decreased expression of the gene has been shown to cooperatewith
p53 in tumorigenesis in mice [38]. Furthermore, inactivating muta-
tions of FBXW7occur in primaryhuman tumors of diverse tissue ori-
gins, with an overall mutation frequency of approximately 6% [18].
These data, together with the oncogenic role of many SCF-FBXW7
substrates, suggest that FBXW7 functions as a tumor suppressor in
human tumorigenesis. We show that CCDC6 seems to be a critical
substrate for FBXW7 that is because ATM-mediated CCDC6 phos-
phorylation at T434 during DNA damage response prevented
FBXW7-mediated CCDC6 degradation and CCDC6 (T434A) mutant
protected cells from genotoxic stress-induced apoptosis.
FBXW7 binds and regulates the abundance of proteins in a
phosphorylation-dependent manner and the known FBXW7 sub-
strates contain at least one conserved Cdc4 phospho-degrons
(CPD) sequence (T/S)PXX(S/T/E). We notice that CCDC6 protein
contains three putative evolution-conserved CPD motifs
(359SPSSS, 413SPRRS and 427TPPPS) and T434 is very close to
one of these CPD motifs (427TPPPS). Indeed, our data suggest that
all these CPD motifs of CCDC6 are required for the efﬁcient recog-
nition by FBXW7 and its subsequential degradation, because
FBXW7 did not interact with and regulate CCDC6 S359A/S413A/
T427A mutant protein. We also speculate that ATM-mediated
CCDC6 phosphorylation at T434 during DNA damage response
may cause a conformation change of CCDC6 which fails to be rec-
ognized by FBXW7. Our data support this theory and indeed CCDC6
(T434A) is more stable than CCDC6WT and could not be efﬁciently
recognized by FBXW7.
In summary, we investigated the underline mechanisms by
which DNA damage response stabilizes CCDC6. ATM mediated
CCDC6 phosphorylation prevents the interaction between FBXW7
and CCDC6 and inhibits the destruction of CCDC6. Considering
the high frequency of gene rearrangements involving CCDC6 in
cancers, the identiﬁcation of the involvement of FBXW7 targets
this protein for destruction will be useful for the establishment
of new therapeutic approaches for cancer treatment.
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